

Aerocrine

Report from the 2011 Annual General Meeting in Aerocrine AB

The Annual General Meeting in Aerocrine was held on Thursday, May 5, 2011, in Stockholm

Anders Williamsson, Scott A. Beardsley, Lars Gustafsson, Staffan Lindstrand, Yvonne Mårtensson and Karl Swartling was re-elected as Board members. Dennis Kane and Rolf Klasson was elected as new Board members. Anders Williamsson was re-elected as Chairman of the Board.

The parent company's and the group's income statements and balance sheets were adopted. It was resolved that no dividend shall be paid and that the year's loss shall be carried forward.

The Meeting resolved that the Nomination Committee for the Annual General Meeting 2012 shall consist of representatives from the four largest shareholders by voting powers (grouped by owner) and the Chairman of the Board, whom shall also convene the Nomination Committee for its first meeting. The composition of the Nomination Committee shall be based on the share register maintained by Euroclear Sweden AB as per August 31, 2011 and be published immediately following the appointment of the Nomination Committee, however by no later than six months prior to the Annual General Meeting.

The Meeting resolved to approve the Board's proposal to amend the Articles of Association, to the effect that the share capital limits be changed to not less than SEK 50,000,000 and not more than SEK 200,000,000, and the limits relating to the number of shares be changed to not less than 100,000,000 and not more than 400,000,000 shares.

The Meeting resolved to approve the Board's proposal to authorize the Board to resolve – at one or several occasions and for the time period until the next Annual General Meeting – to increase the company's share capital by new share issues and to issue warrants and convertible bonds, to the extent that it corresponds to a dilution of not more than 10 percent of the number of shares outstanding at the date of the notice to the 2011 Annual General Meeting, after full exercise of the authorization. New share issues, as well as issues of warrants and convertible bonds, may be made with or without deviation from the shareholders' preferential rights and with or without provisions for contribution in kind, set-off or other conditions.

For full information on each proposal approved by the Meeting, see www.aerocrine.se where documentation relating to the Meeting is available for download.

For further information, please contact:

Paul de Potocki, CEO, phone +46 (0)8 629 07 80

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June 2007.

Aerocrine AB (publ) is required to disclose the information provided herein pursuant to the Securities Markets Act and/or the Financial Instruments Trading Act. The information was submitted for publication at 08:00]p.m. on May 5, 2011.